Previous studies have demonstrated the in vitro and in vivo activity of CC-5013 (Revlimid),
an immunomodulatory analog (IMiD) of thalidomide, in multiple myeloma (MM). In the …

Mammalian target of rapamycin (mTOR) is a downstream serine/threonine kinase of the
PI3K/Akt pathway that integrates signals from the tumor microenvironment to regulate …

The PI3K/Akt/mTOR signal transduction pathway plays a central role in multiple myeloma
(MM) disease progression and development of therapeutic resistance. mTORC1 inhibitors …

Mammalian target of rapamycin (mTOR) inhibitors, such as rapamycin and CCI-779, have
shown preclinical potential as therapy for multiple myeloma. By inhibiting expression of cell …

The mammalian target of rapamycin (mTOR) is centrally located, linking proximal oncogenic
cascades to critical downstream pathways that drive tumor growth. mTOR regulates such …

Although preclinical work with rapalogs suggests potential in treatment of multiple myeloma
(MM), they have been less successful clinically. These drugs allostearically inhibit the …

Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is the second
most common hematological malignancy. The disease is characterized by the accumulation …

Activation of PI3-K-AKT and ERK pathways is a complication of mTOR inhibitor therapy.
Newer mTOR inhibitors (like pp242) can overcome feedback activation of AKT in multiple …

Thalidomide (Thal) can overcome drug resistance in multiple myeloma (MM) but is
associated with somnolence, constipation, and neuropathy. In previous in vitro studies, we …

In vitro studies indicate the therapeutic potential of mTOR inhibitors in treating multiple
myeloma. To provide further support for this potential, we used the rapamycin analog CCI …